Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) EBITDA Margin (2022 - 2024)

Historic EBITDA Margin for Solid Biosciences (SLDB) over the last 3 years, with Q4 2024 value amounting to 53194.67%.

  • Solid Biosciences' EBITDA Margin changed N/A to 53194.67% in Q4 2024 from the same period last year, while for Dec 2024 it was 38155.29%, marking a year-over-year decrease of 480033800.0%. This contributed to the annual value of 38155.29% for FY2024, which is N/A changed from last year.
  • Latest data reveals that Solid Biosciences reported EBITDA Margin of 53194.67% as of Q4 2024.
  • In the past 5 years, Solid Biosciences' EBITDA Margin registered a high of 53194.67% during Q4 2024, and its lowest value of 411.44% during Q2 2022.
  • For the 3-year period, Solid Biosciences' EBITDA Margin averaged around 30335.37%, with its median value being 29926.53% (2024).
  • Within the past 5 years, the most significant YoY rise in Solid Biosciences' EBITDA Margin was 18047200bps (2024), while the steepest drop was 18047200bps (2024).
  • Over the past 3 years, Solid Biosciences' EBITDA Margin (Quarter) stood at 411.44% in 2022, then surged by 6534bps to 26471.07% in 2023, then soared by 101bps to 53194.67% in 2024.
  • Its EBITDA Margin stands at 53194.67% for Q4 2024, versus 42904.88% for Q3 2024 and 31577.27% for Q2 2024.